Company / R&D Expense
Ventyx Biosciences, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$117.0M
FY2024
5-year range
$6.4M / $175.8M
FY2020-FY2024
Trend
-33.4%
vs FY2023
Sector context
#127 of 208
Health Care
What the data says
At $117M, Ventyx Biosciences, Inc.'s r&d expense ranks #127 of 208 in the Health Care sector. Improved from $88M to $117M over the past 2 years.
Based on SEC 10-K filings.
$117M in FY2024 with a 3-year CAGR of +26.0%.
Improved from $88M to $117M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#127 of 208 in Health CareTop 61% of 208This company $117.0M Sector average $644.3M
▼
-81.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +26.0%, indicating consistent growth.
- In FY2024, r&d expense decreased 33.4% year-over-year.
- Ranks #127 out of 208 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $117.0M | -33.4% |
| FY2023 | $175.8M | +100.3% |
| FY2022 | $87.7M | +50.0% |
| FY2021 | $58.5M | +818.6% |
| FY2020 | $6.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026